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Alopecia areata is an autoimmune skin disease resulting in the loss of hair on the scalp and elsewhere on the
body. The disease most often occurs in childhood and affects males and females of all ages. The National
Alopecia Areata Foundation conducts research summits every 2 years to review progress and create new
directions in its funded and promoted research. The Foundation brings together scientists from all disciplines to
get a broad and varied perspective. These summits are part of the Foundation’s main strategic initiative, the
Alopecia Areata Treatment Development Program to accelerate progress toward a viable alopecia areata
treatment.
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This summit titled From Basepairs to Bedside: Innovations in
the Immunology and Clinical Science of Alopecia Areata was
held in Bethesda, Maryland, 29 and 30 November, 2012. It
was convened to review recent progress in understanding the
pathogenesis of alopecia areata and to chart the course for the
future of translational research. It brought together an exciting
group of scientists, immunologists, geneticists, veterinary
scientists, medical experts, translational scientists, clinical
dermatologists, and representatives of government agencies
to discuss innate and acquired immunity, associated auto-
immune diseases, their common immune pathways, and
targeted immunological therapies.
At the Alopecia Areata Clinical Research Summit in
October 2010, participating scientists had stressed the need
to develop a translational platform. Essential to that platform
were biomarker studies; new and established animal models;
a uniform clinical trials protocol; incidence, prevalence,
quality of life and other burden of disease studies; defined
measurements and end points; further genetic and mechanistic
studies; genetic and immunological pathway studies; and
collaboration with the US Food and Drug Administration
(FDA) to pave the way for approval of promising clinical trials.
Advances have been made in all of these areas.
After listening to presentations at this 2012 Alopecia Areata
Research Summit, the scientists in attendance expressed great
satisfaction over the progress being made in providing the
infrastructure needed for the many facets of progressing a drug
through FDA approval.
ALOPECIA AREATA TREATMENT DEVELOPMENT
PROGRAM
These alopecia areata research summits are part of the
National Alopecia Areata Foundation’s (NAAF) main strategic
initiative, the Alopecia Areata Treatment Development
Program (TDP). The first phase of the TDP, started in 2010
clarified and articulated its 7-year mission to accelerate
progress toward a viable alopecia areata treatment. All of
the accomplishments explained above have been part of this
Program with NAAF acting as a concierge, leveraging all of
our available research resources and clinical partnerships.
Our strategic goal is to produce a safe, effective affordable
treatment beneficial to the millions of people with alopecia
areata. This summit was another strategic step on the struc-
tured and focused path toward that goal.
ALOPECIA AREATA RESEARCH GOALS FOR THE NEXT
2 YEARS ESTABLISHED AT THE SUMMIT
Genetics
 Execute combined association and linkage studies using 250
multiplex families from the Alopecia Areata Registry, Bio-
bank, and Clinical Trials Network (formerly known as
National Alopecia Areata Registry).
 Utilize functional genomics with deep sequencing.
 Develop a network plot.
 Determine the percentage of people with alopecia areata
compared with the normal population with specified genes.
 Analyze shared variants among related diseases, including
celiac disease, rheumatoid arthritis, and type 1 diabetes (five
loci are shared between type 1 diabetes and alopecia
areata).
 Increase the number of alopecia areata samples in the
BioBank to 10,000.
 Determine whether there is a genetic basis for disease
subsets, i.e., alopecia areata, alopecia totalis, and alopecia
universalis.
 Analyze National Alopecia Areata Registry, Biobank, and
Clinical Trials Network samples to determine whether
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alopecia areata is a composite of several different disease
processes and the possibility that there are actually many
treatment modalities.
Immunology
 Study how to restore immune privilege.
 Analyze the potential of targeting the interleukin (IL)-15
pathway.
 Identify the protolerance T-cell receptor (TCR) signal; and
then target it pharmacologically.
 Develop TCR sequencing.
 Complete biomarker studies.
Animal models
 Identify and develop mouse and humanized mouse models.
 Validate these models.
 Determine which model will be the best to replicate
alopecia areata.
Clinical
 Finalize and validate the Alopecia Areata Uniform Protocol
for clinical trials.
 Publish quality-of-life studies.
 Publish incidence and prevalence studies.
 Initiate additional burden of disease studies.
 Use pharmacogenomics to predict which patient popula-
tions will respond and which will get side effects.
 Determine the attractive pathways for targeted therapy.
 Continue collaborations with industry and government
agencies to facilitate the regulatory path for alopecia areata
treatments.
Investigators interested in applying for grant funding to study
any of these areas mentioned above should contact the
National Alopecia Areata Foundation for research grant
information.
The following talks were presented. Due to embargos for
other publications, some talks were unable to be published
in these proceedings. Presentations with asterisks (*) are
included.
WELCOME FROM DR KATZ
We were excited to have Dr Stephen Katz, Director of
the National Institute of Arthritis and Musculoskeletal
and Skin Diseases (NIAMS), welcome participants. Dr Katz
stated that one of the fastest growing areas of investment by
the National Institutes of Health is hair investigator–initiated
research.
BACKGROUND ON ALOPECIA AREATA
Dr Maria Hordinsky* introduced meeting participants to
alopecia areata, a complex genetic, immune-mediated disease
that targets anagen hair follicles. Dr Hordinsky reviewed the
clinical presentations of alopecia areata, the pathophysiology
of this disease, and the treatment challenges.
Dr David Norris* summarized the outcomes resulting from
the past three summits and assessed the current state of
alopecia areata research initiatives, clinical trials, and the
National Alopecia Areata Registry. These two doctors success-
fully set the stage for the discussion of new findings in
alopecia areata research in genetics and immunology.
GENETICS OF ALOPECIA AREATA
Dr Angela Christiano* discussed the progress she has made in
genetics research since the last summit. This work greatly
expands our understanding of the genetic architecture of this
highly prevalent autoimmune disease.
Dr John Sundberg* presented the identification of three new
inbred strains in addition to C3H/HeJ and A/J with naturally
occurring alopecia areata in a large aging study, enabling
genome-wide association mapping using large single-nucleo-
tide polymorphism databases, revealing new insight into the
complexity of this disease.
IMMUNOLOGY AND BIOLOGY OF ALOPECIA AREATA
In pursuing cytokines that might be critical to the activation of
killer CD8 T cells, Dr Raphael Clynes and his team identified
elevations of IL-15 in human alopecia areata skin and have
pursued therapeutic approaches to block IL-15 signaling.
These studies establish the pre-clinical rationale for pharma-
cological targeting of CD8 killer T cells in alopecia areata.
Dr Ralf Paus* discussed the clinical consequences of the
hypothesis that alopecia areata is not a single disease entity
but a stereotypic, clinically and histologically distinct hair
follicle response pattern to various inflammatory insults
associated with (e.g., interferon-g (IFNg)-induced) hair follicle
immune privilege collapse.
Dr Thomas Waldmann* discussed two approaches to
dysregulate IL-15 expression: targeting the IL-15 receptor or
its JAK/STAT (Janus-activated kinase/signal transducer and
activator of transcription factor) signaling pathway in mouse
models of autoimmune diseases. Similar IL-15R or IL-15
signaling pathway direct approaches might be effective in
alopecia areata.
Dr Adam Schrum* presented a new technological/analytical
platform designed to allow network analysis of the protein–
protein interactions (PPI) that compose T-cell signaling webs.
Multiplex immunoprecipitation detected by flow cytometry is
designed for high sensitivity and applicability to samples
containing low numbers of T cells.
COMMON CAUSES: RELEVANCE OF ALOPECIA AREATA
TO OTHER AUTOIMMUNE DISEASES
Using a mouse model of vitiligo, Dr John Harris and his team
determined that IFNg and the IFNg-dependent chemokines
CXCL9 (C-X-C motif chemokine ligand 9) and CXCL10 are
critical for the development and maintenance of vitiligo. The
similarities between vitiligo and alopecia areata, including a
dependence on CD8þ T cells and expression of IFNg, strongly
imply a similar pathogenesis.
Dr Matthias von Herrath defended the position that a main
problem in human T1D development and recurrence is
autoimmunity, in spite of ample evidence of the involvement
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of viruses and other environmental and genetic factors in
type 1 diabetes pathogenesis.
To gain further insight into the genetic architecture of
psoriasis, Dr James Elder* and his team conducted a meta-
analysis of three genome-wide association studies and
two independent data sets genotyped on the Immuno-
chip (Illumina, San Diego, CA), involving 10,588 cases and
22,806 controls in total. They identified 15 new disease-
susceptibility regions, increasing the number of psoriasis-
associated loci to 36 for Caucasians. These results portend a
better understanding of shared and distinctive genetic deter-
minants of immune-mediated inflammatory disorders and
emphasize the importance of the skin in innate and acquired
host defense.
EMERGING TECHNOLOGIES
Dr Amos Gilhar* presented the development of an animal
model for alopecia areata in which the clinical phenotype can
quickly be induced within a previously healthy human organ
in vivo.
Dr David Norris presented Dr Yosef Refaeli’s new approach
to generate chimeric mice bearing a human hematopoietic
system.
Dr Julie Segre’s research combines genomics, dermatology,
microbiology, and immunology to explore cutaneous
microbes in relation to healthy skin and dermatological
disorders.
Dr Annemieke de Jong discussed the hypothesis that high-
throughput TCR sequencing may provide patient-specific
molecular tools for monitoring disease activity and response
to therapy and provide insights in phenotype and function of
pathogenic T cells in alopecia areata.
Dr Ali Jabbari presented an update on the Alopecia Areata
Biomarker study aimed to develop a set of exploratory
biomarkers that can later be validated and will be crucial for
monitoring of improvement during clinical trials in alopecia
areata.
Dr Amelia Wall Warner* discussed methods to capitalize
on pharmacogenomic research to rapidly advance develop-
ment of alopecia areata drug therapy.
Maureen McGettigan* presented alopecia areata from a
patient’s perspective.
Dr David Norris* began the second half of the meeting with
a comprehensive review of several key topics discussed on the
first day.
OVERVIEW OF CURRENT TREATMENTS
Dr Jerry Shapiro* presented an overview of the many thera-
peutic options that exist for alopecia areata, including topical,
immunotherapeutic and systemic agents, and injections.
Dr Richard Strick* has been treating extensive cases of
alopecia areata with 1-cholor-2, 4-dinitrobenzene for 35 years
with considerable success and presented the protocol that has
been used.
Dr Madeleine Duvic presented a case of a 35-year-old
white male with a 1-year history of alopecia universalis in
response to targretin gel treatment after beginning systemic
steroids.
TREATMENT DEVELOPMENT PROGRAM
Richard Gelula* presented an overview of the Alopecia Areata
Treatment Development Program, a multi-faceted initiative, a
multi-pronged approach to develop safe and effective treat-
ments for alopecia areata.
Dr Natasha Atanaskova Mesinkovska* presented her work
in the development of a standardized alopecia areata research
protocol to serve as a uniform template, outlining procedures
for all future clinical trials.
Given the lack of reliable and accurate description of
health-related quality-of-life (HRQoL) status in people with
alopecia areata, Dr Tito Mendoza* and his team conducted a
secondary analysis of the National Alopecia Areata Registry to
better understand the HRQoL of people with alopecia areata.
He presented his plan to develop a brief, concise, and
validated patient-reported outcome tool to assess the impact
of alopecia areata on the HRQol of people with the condition.
Dr Rochelle Torgerson presented her study to determine the
incidence of alopecia areata among residents of Olmsted County,
Minnesota, USA and a comparison of the results to those
of a previous study conducted in the same geographic area.
ALOPECIA AREATA REGISTRY, BIOBANK, AND
CLINICAL TRIALS NETWORK
Dr Madeleine Duvic* presented an update on the progress of
the National Alopecia Areata Registry over the past 10 years
and its emergence as a clinical trials network and biobank.
CASE REPORT PRESENTATIONS
Dr Wilma Bergfeld* discussed a young female child, aged
7 years, presented initially with chronic alopecia areata,
which over 2 years progressed to alopecia areata universalis.
Dr Maria Hordinsky presented the case of a 36-year-old
female who reported scalp pruritus with hair loss activity.
Dr John Harris reported two cases that represent a natural
experiment in which separate autoimmune diseases interact
within the skin, with very different results.
Dr Melissa Piliang* presented two young women with the
combination of severe psoriasis, androgen excess, metabolic
syndrome, thyroiditis, and alopecia areata.
Dr Robert Gensure* presented a patient with severe alope-
cia areata, multiple autoimmune diseases (chronic lymphocy-
tic thyroidis, primary ovarian failure), and Down syndrome.
Dr Carolyn Goh* presented a case of alopecia universalis
occurring shortly after treatment of chronic hepatitis C and
discussed the implications this has in understanding the
pathophysiology of alopecia areata.
Dr Lloyd King presented a study in which C3H/HeJ mice
were treated with a laser comb FDA approved for human male
pattern baldness.
CLINICAL POSTERS
Dr Robert Gensure* displayed a poster of his study testing the
effects of a single dose of PTH-collagen binding domain (low
or high dose) in an animal model for alopecia areata, the C3H/
HeJ engrafted mouse.
Dr Vera Price* displayed a poster of two cases: one case
revealed that a strongly positive pull test is not always alopecia
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areata; and a second case revealed that alopecia areata is the
only condition that can cause complete hair loss in 3 months
without any previous symptoms or signs.
BUILDING OUR TRANSLATIONAL PLATFORM: LESSONS
FROM PRE-CLINICAL AND CLINICAL STUDIES
Dr Thanh-Nga Tran* presented a summary of the latest
technologies used to increase cutaneous delivery through the
three different routes, delineating various chemical and physi-
cal methods as well as reviewing various drug delivery systems,
including liposomes, microspheres, and nanoparticles.
Dr Massimo Gadina* discussed the advantages and dis-
advantages of selectively inhibiting JAKs tyrosine kinases for
the treatment of autoimmune diseases.
Dr Sheila Kelly presented an overview of Abatacept (CTLA4–Ig),
a novel fusion protein designed to modulate the T-cell co-
stimulatory signal, in the treatment of autoimmune diseases.
Bimatoprost 0.03% solution is an FDA-approved prescrip-
tion product indicated for the treatment of eyelash hypo-
trichosis. Dr Gurpreet Ahluwalia* presented a clinical study
in which the product was investigated in a double-masked,
randomized, and placebo controlled study in patients who
had significant eyelash loss or hypotrichosis as a result of
chemotherapy.
Dr Amy McMichael* described the use of a common
treatment protocol with a specifically designed module to
study the outcome of excimer laser treatment on moderate-to-
severe scalp alopecia areata in adults.
MECHANISMS FOR FUNDING AND REGULATORY
MATTERS
Dr Ricardo Cibotti presented NIAMS funding opportunities in
functional genomics, ancillary studies of large clinical pro-
jects, and implementation of clinical trials with cooperative
agreements.
Dr John McKew gave an overview of the new National
Center for Advancing Translational Sciences and high-
lights of the translational research programs contained
within.
Dr Heidi Marchand presented drug–development activities
and average development times in the context of the FDA
regulatory processes.
NEXT SUMMIT
The next Alopecia Areata Research Summit will be held
on 4 and 5 December 2014 in Bethesda, Maryland as part
of the Alopecia Areata Treatment Development Program. This
next summit will review and strategically evaluate implica-
tions of findings from research driven by the goals outlined
above. We expect some of the highlights to be: further
demonstrating the disease burden of alopecia areata, includ-
ing the medical, psychosocial, and financial impacts;
clarifying the complexity of this heterogeneous disease with
its wide range of genetic factors that may indicate different
disease subsets and/or processes with potentially many treat-
ment modalities; and further evaluating similarities to other
autoimmune diseases and the potential applicability of their
targets and treatments to alopecia areata. Hopefully, we will
have promising treatments and targets to share with the
autoimmune research community. The National Alopecia
Areata Foundation has provided the support and leadership
to enhance the understanding of alopecia areata. We look
forward to future discoveries.
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